Wednesday, June 21, 2006
Cortex Pharmaceuticals (COR) Reports Negative Results
Cortex Pharmaceuticals (COR) just reported negative results on their Ampakine drug for sleep deprivation, and will now re-evaluate the drug for "internal development." That's the nature of biopharmaceutical investing - punctuated developments.
¶
11:16 AM
Disclaimer:
All ideas, opinions, ratings, and/or forecasts, expressed or implied herein, are for informational purposes only and are in no way
intended to serve as investing advice for anyone else, and should not be construed as a recommendation to invest, trade, and/or speculate in
the markets. All content of this website is purely a record of my personal activity and/or opinions. It is never a recommendation for you. I
don't know you, or your situation. Only you do. Readers should not make any investment decision without first conducting their own thorough
due diligence. Any investments, trades, and/or speculations made in light of the ideas, opinions, and/or forecasts, expressed or implied herein,
are committed at your own risk, financial or otherwise. While the information provided is obtained from sources believed to be reliable, its
accuracy or completeness cannot be guaranteed. Readers must take full responsibility for any actions they take in light of information gleaned
here.
